Cancer-testis antigen expression and immunogenicity in AL amyloidosis

Blood Cancer Journal

Volumn 2, Issue 9, 2012, Pages

  Rosenzweig, M A ^a   Landau, H ^b   Seldin, D ^c   Ohara, C ^c   Girnius, S ^c   Hanson, N ^d   Frosina, D ^d   Sedrak, C ^d   Arcila, M ^d   Comenzo, R L ^e   Giralt, S ^b,f   Gnjatic, S ^d   Jungbluth, A A ^d   Koehne, G ^b,f  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Bone Marrow Transplant Service   (United States)

^c BOSTON MEDICAL CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

AL amyloidosis; cancer testis antigens; stem cell transplantation

Indexed keywords

CANCER TESTIS ANTIGEN;

ADULT; AMYLOIDOSIS; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIGHT CHAIN AMYLOIDOSIS; MALE; PLASMA CELL; PLASMA CELL DYSCRASIA; PROGNOSIS; TISSUE DISTRIBUTION; TISSUE SECTION; TREATMENT RESPONSE;

EID: 84871035125     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2012.32     Document Type: Article

References (34)

1. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79: 1817-1822.
2. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337: 898-909.
3. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45-59.
4. Gertz MA, Zeldenrust SR. Treatment of immunoglobulin light chain amyloidosis. Curr Hematol Malig Rep 2009; 4: 91-98.
5. Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chainassociated (AL) amyloidosis. Clin Lymphoma 2003; 3: 241-246.
6. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109: 492-496.
7. Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM, Witzig TE, Fonseca R et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003; 10: 257-261.
8. Comenzo RL, Hegenbart U, Sanchorawala V. High rates of overall and complete haematologic response in a prospective phase 1/2 study of weekly and twiceweekly bortezomib in relapsed AL amyloidosis. Amyloid J Protein Folding Disord 2010; 17: 83-84.
9. Schonland SO, Lokhorst H, Buzyn A, Leblond V, Hegenbart U, Bandini G et al. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood 2006; 107: 2578-2584.
10. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188: 22-32.
11. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-625.
12. Knuth A, Wolfel T, Klehmann E, Boon T, Meyer zumBu? schenfelde KH. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci USA 1989; 86: 2804-2808.
13. Fiszer D, Kurpisz M. Major histocompatibility complex expression on human, male germ cells: a review. Am J Reprod Immunol 1998; 40: 172-176.
14. Westbrook VA, Schoppee PD, Diekman AB, Klotz KL, Allietta M, Hogan KT et al. Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell lines. Clin Cancer Res 2004; 10: 101-112.
15. Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 2003; 3: 9.
16. Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 2005; 106: 167-174.
17. Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007; 109: 1103-1112.
18. Cho HJ, Caballero OL, Gnjatic S, Andrade VC, Colleoni GW, Vettore AL et al. Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). Cancer Immun 2006; 6: 12.
19. Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS et al. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 2008; 8: 2.
20. van Duin M, Broyl A, de Knegt Y, Goldschmidt H, Richardson PG, Hop WC et al. Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica 96: 1662-1669.
21. Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S et al. Cancertestis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica 2010; 95: 785-793.
22. Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C et al. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res 2009; 15: 1343-1352.
23. Jungbluth AA, Stockert E, Chen YT, Kolb D, Iversen K, Coplan K et al. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer 2000; 83: 493-497.
24. Landry C, Brasseur F, Spagnoli GC, Marbaix E, Boon T, Coulie P et al. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer 2000; 86: 835-841.
25. Jungbluth AA, Chen YT, Busam KJ, Coplan K, Kolb D, Iversen K et al. CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. Int J Cancer 2002; 99: 839-845.
26. Zhuang R, Zhu Y, Fang L, Liu XS, Tian Y, Chen LH et al. Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2. Cancer Immun 2006; 6: 7.
27. Rimoldi D, Salvi S, Schultz-Thater E, Spagnoli GC, Cerottini JC. Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family. Int J Cancer 2000; 86: 749-751.
28. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001; 92: 856-860.
29. Cohen AD, Lu P, Gnjatic S, Hoffman J, Ritter E, Zhou P et al. MAGE-A3 or NY-ESO1 expression and spontaneous antibody responses to NY-ESO1 in newly diagnosed multiple myeloma patients are associated with worse overall survival. ASH Annual Meeting Abstracts 2008; 112: 5110.
30. Anderson Jr. LD, Cook DR, Yamamoto TN, Berger C, Maloney DG, Riddell SR et al. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother 2011; 60: 985-997.
31. Bochtler T, Hegenbart U, Cremer FW, Heiss C, Benner A, Hose D et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 2008; 111: 4700-4705.
32. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108: 2520-2530.
33. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11: 8055-8062.
34. Gnjatic S, Old LJ, Chen YT. Autoantibodies against cancer antigens. Methods Mol Biol 2009; 520: 11-19.